Assistant de documentation des composantes du FLIPI original de 2004 pour le lymphome folliculaire

État

clinical-review-pending

Version de la méthode

Solal-Celigny et al. original 2004 Follicular Lymphoma International Prognostic Index (FLIPI) arithmetic, engine original-flipi-2004-v1: one component each for completed age at diagnosis >60 years; clinician-established Ann Arbor stage III or IV; blood hemoglobin <12 g/dL (<120 g/L); pretreatment serum total LDH above the same issuing report's local upper limit of normal; and clinician-verified five or more historical involved nodal areas. Exact age 60, stage I or II, hemoglobin 12 g/dL or 120 g/L, serum total LDH equal to its same-report local ULN, and zero to four historical involved nodal areas each contribute zero. Hemoglobin in g/L is normalized by g/dL = g/L / 10 without rounding. The historical nodal-area category is accepted only as externally clinician verified and is never derived from an anatomy checklist, individual-node count, extranodal-site count, or tumor-mass count. All five verified values from one complete initial pretreatment assessment are required. Output is limited to the raw 0-5 count, five component booleans, and exact entered-value audit; no group, risk adjective, survival or probability estimate, diagnosis, prognosis, treatment, disposition, recommendation, or management decision is supplied.

Population

Adults age 18 years or older with histologically confirmed, newly diagnosed, previously untreated systemic follicular lymphoma compatible with the independently specialist-selected original FLIPI disease subtype and pathway. The source collected 4,167 cases diagnosed in 1985-1992 under Working Formulation and/or Kiel classifications, used 1,795 complete cases to build the model, and externally validated it in 919 patients. This v1 workflow is deliberately narrower: original-FLIPI applicability and compatible disease pathway, Ann Arbor stage, historical nodal-area category, hemoglobin identity, unit and timing, serum total LDH and its same-report local ULN identities and units, and one complete initial pretreatment assessment must all be independently confirmed. Historical pre-rituximab transport must be explicitly acknowledged.

Limites et exclusions

Pediatric disease or pediatric-type follicular lymphoma; in-situ follicular B-cell neoplasia; grade 3B or another aggressive lymphoma pathway; transformed or composite disease or use to infer transformation; primary cutaneous follicle-centre lymphoma; duodenal-type or another site-specific entity; another lymphoma histology; relapsed or refractory disease; post-treatment reassessment; or use to establish a diagnosis, subtype, pathway, or source applicability. · Missing, unknown, inferred, imputed, defaulted, carried-forward, incomplete, mixed-timepoint, later, or post-treatment inputs; an app-derived Ann Arbor stage; an anatomy-derived nodal-area category; an individual-node, extranodal-site, or tumor-mass count substituted for the historical involved-nodal-area category; or an unverified stage, category, timing, source, or identity. · Serum total LDH without its same issuing report local ULN; a universal absolute LDH threshold; unsupported LDH units; different reports or timepoints; non-serum or non-total-LDH values; a ratio entered in place of source measurements; unsupported hemoglobin units or analyte identity; rounded values; or an unverified analyte, specimen, report, reference limit, or unit identity. · FLIPI2; PRIMA-PI; m7-FLIPI; FLEX; FLIPI24; POD24; GELF or BNLI criteria; source-defined group cutoffs; any group, risk adjective, survival or mortality estimate, probability, individual prognosis, diagnostic or transformation conclusion, treatment, disposition, recommendation, management, or care decision.

• https://pubmed.ncbi.nlm.nih.gov/15126323/
• https://doi.org/10.1182/blood-2003-12-4434
• https://ashpublications.org/blood/article/104/5/1258/18907/Follicular-Lymphoma-International-Prognostic-Index
• https://doi.org/10.1016/j.annonc.2025.07.014
• https://ashpublications.org/blood/pages/public-access

Outil importé de la bibliothèque PharmaTek de MDose. Aucune date de révision clinique indépendante n’est documentée dans cette version.

Bibliothèque source

PharmaTek · MDose

Version importée

4b66536936ed

État de publication

Révision clinique en cours